Arena maps out its one-year plan for lorcaserin

Arena Pharmaceuticals ($ARNA) and its partners at Eisai have had a chance to review exactly what the FDA wants to see on their experimental weight drug and promise to have a complete response shipped over by the end of next year. But the news failed to impress investors, with the biotech's shares sagging close to 10 percent this morning.

Arena's lorcaserin was one of two obesity drugs that failed to make the cut--so far--at the FDA this fall. And with regulators zeroing in on its potential safety issues, a number of analysts have adopted a skeptical view of its chances in 2011. But after Orexigen's Contrave won an advisory vote recently, the chances for Vivus's Qnexa seemed to brighten considerably.

Last October's CRL asked for new data from a one-year study of obese and diabetic patients and asked Arena to come up with one or more independent experts to take a second look at tumor data to see if the agency's cancer worries can be addressed. In the event the FDA is left unconvinced, "additional clinical studies may be required to obtain a more robust assessment of lorcaserin's benefit-risk profile."

One of Arena's lingering issues has been a matter of trust. Analysts and investors alike felt burned after the FDA exposed animal studies that raised the cancer issue. That's something they felt should have come first from the developer.

"The meeting discussions reinforce our position that we have a path forward to seek approval of lorcaserin," said an ever-bullish Arena CEO Jack Lief in a statement. "Based on guidance we have received from the agency, we are executing several activities and expect to resubmit the lorcaserin NDA by the end of 2011. As we continue discussions with the to refine elements of our plan, we may identify ways to shorten this timeline."

- read the Arena release
- and here's the Reuters story

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.